ZNTL Zentalis Pharmaceuticals, Inc.
$1.98▼ -4.35%
Healthcare
Other
Volume 1.72M
Avg Volume (10D) 1.28M
Key Metrics & Fundamentals
Market Cap
$194.28M
P/E Ratio
–
Div Yield
0.00%
52W Range
1.21 - 6.95
% vs 50 MA
-35.16%
% vs 200 MA
-43.04%
RSI-14
29.6
MACD Histogram
+0.0100
Beta (1Y vs SPY)
2.01
Free Cash Flow
-$37.24M
Gross Rev
$0
Gross Profit
$0
EBITDA
-$46.48M
COGS
–
Operating Exp
$44.39M
Operating Income
-$44.39M
EBIT
-$44.39M
Pretax Income
-$42.15M
Net Income
-$42.29M
EPS (Diluted)
-0.59
Price & Volume History
Loading chart…
Recent News
Zentalis Pharmaceuticals Reports Survival Data for Ovarian Cancer Drug Azenosertib
MT Newswires · Oct 23, 2026 12:41 PM ET
Zentalis Pharmaceuticals Announces Meaningful Median Overall Survival Data in Cyclin E1-Positive Platinum-Resistant Ovarian Cancer from DENALI Part 1b to be Presented at the ESMO Congress 2026
GlobeNewswire · Oct 23, 2026 10:15 AM ET
Zentalis Pharmaceuticals Announces First Overall Survival Data for Azenosertib from DENALI Part 1b Published in ESMO Congress 2026 Abstract
GlobeNewswire · Oct 18, 2026 6:05 PM ET
Zentalis Pharmaceuticals Shares Rise After Leerink Upgrade
MT Newswires · Oct 5, 2026 3:32 PM ET
Zentalis Pharmaceuticals Shares Rise After Leerink Assumes Coverage With Outperform Rating
InvestorsHub · Oct 5, 2026 7:55 AM ET
Leerink Upgrades Zentalis Pharmaceuticals to Outperform From Market Perform, Price Target is $8
MT Newswires · Oct 5, 2026 7:08 AM ET
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire · Oct 1, 2026 5:10 PM ET
William Blair Initiates Zentalis Pharmaceuticals at Outperform
MT Newswires · Sep 16, 2026 6:53 AM ET
Zentalis Pharmaceuticals to Participate in Upcoming Investor Conferences
GlobeNewswire · Sep 2, 2026 4:05 PM ET
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire · Sep 1, 2026 5:15 PM ET
Financial Overview - Income Statement
Quarterly
Dec 2024
See ZNTL's money flow as a full page
Social Sentiment
Loading Reddit posts…
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.